Bone is continually recycled to maintain its strength through the competing action of osteoclasts, cells that break down aging bone, and osteoblasts, which build new bone. Osteoclasts also play a central role in common diseases that erode bone, where two signaling molecules, TNFá and RANKL, cause too much bone breakdown.
Both are known to turn on the nuclear factor kappa B complex (NF-êB), which turns on genes that cause the stem cell precursors of osteoclasts to mature and start eating bone. While both TNFá and RANKL encourage bone loss, the current study argues that TNFá and RANKL have different effects on levels of a key inhibitory protein within the NF-êB pathway called NF-êB p100, with important consequences for drug design.
The NF-êB pathway as a whole signals for more active osteoclasts, but NF-êB p100 (p100) interferes with the ability of that same pathway to pass on the bone loss signal. While both TNFá and RANKL activate NF-êB signaling, RANKL efficiently converts p100 into a form that no longer blocks NF-êB pathway signaling and that leads to bone loss. In contrast, the current study is the first to show that TNFá lets p100 build up. Thus, TNFá both causes bone loss through NF-êB signaling and limits it via p100 accumulation.
Experiments found further that mice genetically engineered to lack NF-êB2p100 suffered more severe joint erosion and inflammation than their normal littermates in the face of TNFá. TNFá, but not RANKL, also increased levels of a protein in osteoclast precursors called TNF receptor-associated factor 3 (TRAF 3), which may help NF-êB p100 block osteoclast formation and inflammation.
"While further studies will be required to confirm and detail this mechanism, our results argue strongly that increasing levels of either TRAF3 or NF-êB p100 could represent a powerful new way to limit bone destruction and inflammation-induced bone loss seen in osteoporosis and rheumatoid arthritis," said Brendan Boyce, M.D., professor within the Department of Pathology and Laboratory Medicine at the University of Rochester Medical Center, and the study's corresponding author. "NF-êB p100 levels may vary with each person's genes, making some more susceptible to TNFá-driven disease. Future solutions may be local delivery of p100 into diseased joints via gene therapy, or to target with a drug the enzyme, NIK, which otherwise limits the p100 supply."
At the Center of Bone Loss and Inflammation
Drugs that block the function of TNFá are blockbusters (e.g. Enbrel, Humira and Remicade) because they effectively prevent bone loss and inflammation in most patients with rheumatoid arthritis. They have also been shown to reduce bone loss in women early after menopause.
Other studies, however, have suggested that TNFá cannot cause precursor cells to become osteoclasts unless RANKL first "primes" them. The debate has been spirited because it goes to which molecule should be targeted in near-future attempts to design more precise drugs.
The current results show that TNFá can signal for bone loss without RANKL, providing NF-êB p100 is also absent. By engineering mice with neither RANKL nor NF-êB p100, Boyce and colleagues found that TNFá had greatly increased ability to signal for osteoclast maturation and bone loss in this scenario.
Another unexpected result was measured in changes in gene expression, the process by which information encoded in DNA chains is used to build proteins that make up the body's structures and carry it messages. The team found that mice engineered to over-express TNFá, but also to lack NF-êB p100, had significantly increased inflammation in their joints when compared to mice with high TNFá levels, but with p100 present to counter it.
Along with Boyce, the study was led by Zhenqiang Yao and Lianping Xing in the Department of Pathology and Laboratory Medicine at the University of Rochester Medical Center. The study was funded in part by the National Institutes of Health.
"We believe NF-êB p100 limits not only osteoclast maturation, but also the number of inflammatory cells attracted to the joints in response to TNFá," Boyce said. "If confirmed, it would mean that p100 has more than one role in more than one major bone disease, and thus would create new opportunities to reverse disease by manipulating p100 levels."
Greg Williams | EurekAlert!
Why might reading make myopic?
18.07.2018 | Universitätsklinikum Tübingen
Unique brain 'fingerprint' can predict drug effectiveness
11.07.2018 | McGill University
For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.
To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...
For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.
Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...
Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.
A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...
Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.
"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....
Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.
Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...
13.07.2018 | Event News
12.07.2018 | Event News
03.07.2018 | Event News
19.07.2018 | Earth Sciences
19.07.2018 | Power and Electrical Engineering
19.07.2018 | Materials Sciences